The price of Xolair 150 mg can vary significantly depending on factors such as insurance coverage, pharmacy, and geographic location. Without specific insurance details or a prescription, providing an exact retail price is not possible.
How much does Xolair cost without insurance?
The out-of-pocket cost for Xolair can be substantial. One source indicates a price of approximately $1,028.51 for 100 mg/2 mL of Xolair, suggesting that a 150 mg dose would be proportionally higher [1]. However, actual cash prices at different pharmacies may differ.
What financial assistance programs are available for Xolair?
For patients who qualify, financial assistance programs may be available to help reduce the cost of Xolair. Novartis, the manufacturer, offers a program called "Novartis Patient Assistance Foundation." Information about eligibility and application processes can typically be found on the manufacturer's official website or through patient support services.
How does insurance affect the price of Xolair?
Insurance coverage plays a crucial role in determining the final cost of Xolair for a patient. Many insurance plans include co-pays or co-insurance for prescription medications, which can significantly lower the amount an individual pays. However, the specific terms of a patient's insurance plan will dictate the exact out-of-pocket expense. Some plans may also have preferred pharmacies or require prior authorization before covering Xolair.
When does Xolair's patent expire?
Understanding patent expiry is important for anticipating potential lower-cost generic alternatives. According to DrugPatentWatch.com, the patent status and expiry dates for Xolair (omalizumab) can be complex and may involve multiple patents [2]. Information on specific patent expiry dates for Xolair is available through patent databases and resources like DrugPatentWatch.com.
What are the approved uses for Xolair?
Xolair is approved for treating several conditions. These include moderate to severe persistent allergic asthma in patients aged 6 and older whose symptoms are not controlled by inhaled corticosteroids [1]. It is also indicated for chronic idiopathic urticaria (CIU) in patients aged 12 and older whose hives are not relieved by antihistamine treatment [1]. Additionally, Xolair is used for treating nasal polyps in adults alongside nasal corticosteroids when such treatments do not provide adequate control [1].
---
Sources:
[1] https://www.goodrx.com/xolair
[2] https://drugpatentwatch.com/